Examkin

Question

Difficulty: HardNeurocognitive Disorders

An 80-year-old man, a former university professor, visits his outpatient provider accompanied by his daughter. She expresses concern that over the past 18 months, he has been repeatedly misplacing important documents, forgetting appointments, and struggling to manage his finances. Last week, he was found wandering several blocks from his house, unable to remember the route back. Vital signs are stable, and the neurological examination shows no focal deficits. The provider plans a comprehensive evaluation and anticipates a long-term management strategy for presumed Alzheimer disease.

Arrange the following clinical steps in the appropriate chronological sequence for the standard diagnostic evaluation and progressive longitudinal management of this patient's condition.

  1. 1Administer an objective cognitive screening instrument (e.g., Montreal Cognitive Assessment) and evaluate functional status.
  2. 2Obtain standard laboratory indices (e.g., TSH, vitamin B12) and structural neuroimaging to exclude secondary or reversible etiologies.
  3. 3Initiate symptomatic pharmacotherapy with a centrally acting acetylcholinesterase inhibitor.
  4. 4Augment pharmacotherapy with an N-methyl-D-aspartate (NMDA) receptor antagonist.
  5. 5Transition to full-time skilled nursing care and prioritize palliative approaches.

Answer

The correct sequence begins with the objective quantification of the cognitive deficit, followed by ruling out secondary causes via labs and imaging, initiating first-line monotherapy for mild-to-moderate disease, escalating to combination therapy as the disease reaches the moderate-to-severe stage, and finally focusing on palliative and skilled care in the terminal stages.
The standard of care for evaluating and managing progressive memory loss follows a strict chronological pathway. First, the physician must objectively confirm the impairment using validated cognitive scales. Second, neuroimaging and laboratory tests must be obtained to exclude reversible causes such as hypothyroidism, neurosyphilis, B12 deficiency, or structural intracranial lesions. Only after a clinical diagnosis of major neurocognitive disorder (likely Alzheimer disease) is established should first-line pharmacotherapy with an acetylcholinesterase inhibitor (donepezil) be started. As the disease naturally progresses over years to a moderate-to-severe stage, the addition of an NMDA receptor antagonist (memantine) is indicated. Finally, in the late/terminal stages of the disease, when the patient is fully dependent and medications offer little to no functional benefit, the focus appropriately shifts toward skilled nursing and palliative care.

Step-by-Step Solution

1
Administer a cognitive screening tool (e.g., MoCA or MMSE).
Establishes the presence and severity of objective cognitive decline.
It is necessary to confirm that the patient's cognitive deficits are genuine and measurable before proceeding with an extensive medical workup.
2
Order screening labs (TSH, B12, CMP, CBC) and a noncontrast Head CT or Brain MRI.
Excludes potentially reversible causes of dementia.
Guidelines mandate ruling out metabolic disturbances, nutritional deficiencies, and structural lesions before diagnosing Alzheimer disease.
3
Start an acetylcholinesterase inhibitor (AChEI).
Provides symptomatic benefit for mild-to-moderate Alzheimer disease.
AChEIs (donepezil, rivastigmine, galantamine) are the standard first-line pharmacotherapy following a formal diagnosis.
4
Add memantine.
Augments therapy for advancing disease.
Memantine, an NMDA receptor antagonist, is indicated only when the patient's condition progresses from mild to moderate-to-severe Alzheimer disease.
5
Implement palliative care and skilled nursing transition.
Ensures safety and comfort in end-stage dementia.
When patients completely lose the ability to perform basic activities of daily living (ADLs) and require 24/7 care, the clinical focus shifts to custodial and palliative care.

Key Concept

Diagnostic algorithm and progressive pharmacological management of Alzheimer disease
Rate this question

Topics

Neurocognitive Disorders

More questions from this topic